Navigation Links
Validus Pharmaceuticals Further Expands Marketed U.S. Portfolio with Product Lines Purchased from Leading Healthcare Company
Date:12/14/2015

PARSIPPANY, N.J., Dec. 14, 2015 /PRNewswire/ -- Validus Pharmaceuticals LLC ("Validus"), together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US:  Anzemet® (dolasetron mesylate) Injection and Tablets, Claforan® (cefotaxime) Injection/IM/IV, Demerol® (meperidine hydrochloride) Tablets, Drisdol® (ergocalciferol) Capsules and Oral Solution, Hiprex® (methenamine hippurate) Tablets, Lasix® (furosemide) Tablets, Norpramin® (desipramine hydrochloride) Tablets and Trental ® (pentoxifylline) Tablets.

Wood Creek acquired the Sanofi US products on December 10, 2015 through a new company, US Pharmaceuticals Holdings II LLC. Validus will serve as the exclusive manager for the ex-Sanofi US lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represents a significant growth catalyst for the company.

"The management and marketing of these significant new product lines fulfills another major step in Validus Pharmaceuticals' strategic plan for continued growth," commented James Hunter, Validus CEO. "Adding these lines of medications immediately enables Validus to serve additional large and growing markets and continues to expand our presence in the U.S. pharmaceutical market."

"The acquisition of U.S. rights to these Sanofi US products continues to demonstrate our belief in, and commitment to, the mature branded pharmaceuticals market," said Matthew Sandoval, Wood Creek Managing Director.  "This is another in a series of transactions completed with large pharmaceutical companies by Wood Creek.  We are excited about the potential for our strategy."

As manufacturing and distribution of these products transitions to Validus, the company is working rapidly in order to assure both physicians and patients of a continued product supply under their label. Validus will be communicating directly with distributors and prescribing physicians regarding the availability of all these products.

About Validus Pharmaceuticals LLC

Validus Pharmaceuticals LLC is a Parsippany, New Jersey-based specialty pharmaceutical company focused on the acquisition, reformulation, and marketing of FDA-approved prescription products that satisfy unmet clinical needs.  To fulfill this mission, Validus seeks out and acquires marketed products that have well established safety profiles as well as significant clinical benefits.

For additional information please visit http://www.validuspharma.com/

About Wood Creek Capital Management, LLC

Wood Creek is an investment manager at the forefront of private assets investing.  Headquartered in New Haven, Connecticut Wood Creek had approximately $2.8 billion of assets under management as of June 30, 2015.  Wood Creek is a leading investor in intangible assets, including pharmaceutical brands.

For additional information please visit http://www.woodcreek.com/

Contacts:

Josh Weinstein – Media Contact
jwEinstein Strategic Messaging, Inc.
jwemc2@rcn.com 
610-438-8853

James Hunter, CEO
Validus Pharmaceuticals LLC
jhunter@validuspharma.com
973.265.2777


'/>"/>
SOURCE Validus Pharmaceuticals LLC
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
2. RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016
3. Imprimis Pharmaceuticals Reports Results of Independent Third Party Potency Analysis of its Compounded Pyrimethamine and Leucovorin Capsules
4. Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
5. PharmaBoardroom Releases New Romania Pharmaceuticals Report
6. Rock Creek Pharmaceuticals to Present at Biotech Showcase 2016
7. Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
8. SCILEX Pharmaceuticals Announces Executive Hires
9. World Payer Hotspots in Specialty & Oncology - Potential Areas for Increased Management in Specialty and Oncology Pharmaceuticals
10. Niche Pharmaceuticals, Inc. Asks "Are You Ready to Get Your Life Back from Chronic Migraines?"
11. Immune Pharmaceuticals CEO Updates Shareholders On Company Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... ... ... The business of healthcare management is complex. From providing the best care to ... and physical safety, there are many things to keep up with. Very often, building ... to provide their insights on healthcare facility maintenance to attendees at the North ...
(Date:2/20/2020)... MONTCLAIR, N.J. (PRWEB) , ... February 20, 2020 ... ... Hilton Scottsdale Resort, 6333 North Scottsdale Road, in Arizona, will be a timely ... hours of relevant, practical instruction in the management of chronic pain. , In ...
(Date:2/19/2020)... ... ... Drs. Mario Canal and Ben Calem will host the Pinnacle Dental Study Club ... course features guest speaker, Dr. Amanda Seay, and will focus on aesthetic dentistry as ... full mouth dental implants, are a major focus at Canal Calem Periodontics as a ...
Breaking Medicine Technology:
(Date:2/28/2020)... ... February 28, 2020 , ... Attainia , ... Healthcare has selected Attainia’s new equipment planning solution to manage their fast growing, ... , “We’re thrilled to have Sovereign Healthcare use Attainia as an essential tool ...
(Date:2/26/2020)... ... February 26, 2020 , ... The epilepsy ... robotic device that helps pinpoint the origin of epileptic seizures on a patient. ... called a Robotized Surgical Assistant, or ROSA. With assistance from the robot, neurosurgeons ...
(Date:2/23/2020)... ... 22, 2020 , ... Although many people thrive on praise, ... reveals that some people who dismiss compliments struggle with their sense of self-worth, ... took the Emotional Intelligence Test, Queendom researchers focused on two distinct ...
(Date:2/21/2020)... ... 21, 2020 , ... Cosmetic surgery continues to grow in ... Surgeons (ASPS). According to the ASPS, there were 17.7-million cosmetic procedures performed in ... year. The American Society of Plastic Surgeons reported that some of the most ...
(Date:2/20/2020)... ... February 20, 2020 , ... Millennial women are flocking to cosmetic ... in Milford, Penn requesting treatments to achieve “ Rich Girl Face .” In fact, ... it is slowing down into 2020. It’s a look inspired by the signature bee-stung ...
Breaking Medicine News(10 mins):